IND Enabling Package
Providing custom synthesis, PROTAC technology, DNA-encoded library screening, and scale-up synthesis capabilities.
Extensive pharmacology studies with 400+ oncology and 230+ non-tumor disease models, plus GLP-compliant toxicology evaluations.
End-to-end CMC services, ensuring compliance, consistency, and scalability from early development to clinical phases.
At Medicilon, we drive innovation and efficiency in global drug development, helping clients achieve their R&D goals.
Our culture of innovation, collaboration, and a people-first approach fosters a dynamic work environment. We prioritize talent development and invest in our people, providing opportunities for sustainable growth.